Back to search

Clemson University

Product Liability Litigation: An Issue of Merck and Lawsuits Over Vioxx

Abstract

dc:description.abstract

Merck & Co., Inc. pulled Vioxx, a $2.5 billon a year nonsteroidal anti-inflammatory drug, off the shelf in September 2004. The removal followed a study that was published reporting Vioxx increased the risk of cardiovascular events after long-term use. In the years since then, many lawsuits have been filed against Merck. This paper examines the incentive to recall a product and the effects of Merck pulling Vioxx from the shelves. Using the market's expected internal rate of return for Merck, I calculate the expected profits from future Vioxx sales. I then use data on financial effects, along with the outcomes of cases already heard, to show how the market value of Merck reflects their probability of winning legal cases concerning Vioxx.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy (PhD)
Level thesis:degree_level
Dissertation
Discipline thesis:degree_discipline
Applied Economics

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Rotthoff, Kurt
Contributors dc:contributor
  • Maloney, Michael T

Subjects

dc:subject × 7

Identifiers

dc:identifier.*
Repository record dc:identifier
https://open.clemson.edu/all_dissertations/63

Chain of custody

source
Harvested from
Clemson University
Base URL
open.clemson.edu/do/oai/
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Rotthoff, Kurt. Product Liability Litigation: An Issue of Merck and Lawsuits Over Vioxx. Dissertation thesis, https://open.clemson.edu/all_dissertations/63